ClinicalTrials.govpublic full text
A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer
head and neck cancer, nsclc, dbpr112, egfr mutated nsclc, squamous cell cancer of head and neck, maximum tolerated dose, recommended phase 2 dose, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 966786
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.